D59.11
Warm autoimmune hemolytic anemia
Clinical Classification Guidelines
Inclusion Terms
- Warm type (primary) (secondary) (symptomatic) autoimmune hemolytic anemia
- Warm type autoimmune hemolytic disease
Medical Intelligence & Overview
Warm autoimmune hemolytic anemia (AIHA) is a condition where the body's immune system mistakenly attacks its own red blood cells, leading to their destruction. This form of anemia is characterized by the harmful activity of autoantibodies that target red blood cells at body temperature, typically causing symptoms like fatigue and weakness. It may develop on its own (primary) or as a result of other health issues (secondary). Recognizing and understanding this condition is important for managing symptoms and seeking appropriate medical care.
Causes & Symptoms
Clinical Causes: Primary (idiopathic) - no identifiable underlying cause; the immune system spontaneously produces autoantibodies against red blood cells. Secondary - linked to other health conditions such as lymphomas, autoimmune diseases like lupus, certain infections, or reactions to medications. Associated medications - some drugs may trigger the immune response leading to autoimmune hemolytic anemia.
Key Symptoms: Fatigue and weakness due to reduced oxygen-carrying capacity of the blood. Pale or jaundiced skin, as a result of increased breakdown of red blood cells. Shortness of breath, especially during exertion. Rapid heartbeat (tachycardia). Dark-colored urine due to hemoglobin breakdown products. Fever and chills in some cases. Enlarged spleen (splenomegaly), which can contribute to increased red blood cell destruction.
Diagnostic & Treatment
Diagnosis Path: The diagnosis of warm autoimmune hemolytic anemia involves several tests: - Blood tests including a complete blood count (CBC) to assess red blood cell levels. - Direct antiglobulin test (DAT or Coombs test) to detect autoantibodies attached to red blood cells. - Blood smear examination to observe red blood cell morphology. - Reticulocyte count to evaluate bone marrow response. - Additional tests may be conducted to identify underlying causes or secondary conditions.
Treatment Protocols: Managing warm autoimmune hemolytic anemia often involves: - Corticosteroids to suppress immune system activity and reduce autoantibody production. - Immunosuppressive medications if steroids are ineffective. - In severe cases, treatments like plasma exchange or splenectomy (removal of the spleen) may be considered. - Management of underlying conditions in secondary cases. - Supportive care includes blood transfusions when necessary and ongoing monitoring of blood counts.
Clinical Advice & FAQs
Billing Guidance
Is D59.11 a billable ICD-10 code?
Yes, D59.11 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D59.11?
Clinical documentation must specify the nature of Warm autoimmune hemolytic anemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference